NCT06480630Not yet recruitingPhase 2
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Source: ClinicalTrials.gov · Last updated 28 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- First submitted
- 25 Jun 2024
- Start date
- 1 Jul 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT06480630
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 39
- From 1 Jul 2024 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Non-malignant hematologic disorders;
- History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
- Uncontrolled bacterial, viral, or fungal infections. "Uncontrolled" is defined as lack of clinical improvement or progression despite adequate antimicrobial therapy;
- HIV infection or active hepatitis B or C virus infection;
- Substance abusers; subjects with uncontrolled psychiatric disorders; individuals with cognitive dysfunction;
Other
- Pregnant or lactating women;
- Participation in similar clinical studies within the past 3 months;
- Subjects deemed unsuitable by the investigator (e.g., those expected to be unable to adhere to treatment due to financial constraints).
Who the study is looking for
- Malignant hematologic disorders;
- Patients undergoing UCBT;
- Female patients of childbearing potential must have a negative pregnancy test and agree to use effective contraception during treatment and for the following year.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.